Anti-PD-L2 Antibody, clone 24F.10C12

32160702

NA.41

Programmed cell death 1 ligand 2 (UniProt Q9BQ51; also known as B7-DC, B7 dendritic cell molecule, B7-H2, Butyrophilin B7-DC, CD273, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2) is encoded by the PDCD1LG2 (also known as B7DC, CD273, PDCD1L2, PDL2) gene (Gene ID 80380) in human. PD-1 and PD-1 ligands 1&2 (PD-L1 and PD-L2) are B7:CD28 family members that regulate T cell activation and peripheral tolerance. When engaged together with the TCR, the interaction of PD-1 with its ligands delivers an inhibitory signal to T cell proliferation and cytokine production. While PD-L1 is broadly expressed in hematopoietic and nonhematopoietic cells, PD-L2 expression is highly restricted to antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages. The PD-1 pathway plays a key role in the progressive loss of effector T cell responses during chronic HIV infection. Under some conditions, blockade of this pathway is able to restore many T cell functions. PD-L2 is initially produced with signal peptide (a.a. 1-19) sequence, the removal of which yields the mature protein with a large extracellular (a.a. 20-220) region that contains an Ig-like V-type domain (a.a. 21-118) and an Ig-like C2-type domain (a.a. 122-203), followed by a transmembrane domain (a.a. 221-241) and a cytoplasmic tail (a.a. 242-273).

Clone 24F.10C12 immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L2, but not the untransfected cells or cells transfected with human PD-L1 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Reactivity toward spliced isoform 2 (PD-L2II) and isoform 3 (PD-L2III) has not been determined.

Recombinant human PD-L2.
Epitope: Extracellular domain.

Research Sub Category
Apoptosis - Additional
Flow Cytometry Analysis: 0.1 µg from a representative lot detected PD-L2-positive human PBMCs.
Flow Cytometry Analysis: A representative lot immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L2, but not the untransfected cells or cells transfected with human PD-L1 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected a small induction of surface PD-L2 expression on human PBMCs in culture upon IFN-gamma stimulation (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and employed to detect surface PD-L2 expression on PBMC-derived dendric cells (DCs). An upregulated PD-L2 expression was seen among mature DCs (mDC) than immature DCs (iDC), the levels of PD-L2 were reduced upon pretreatment of mDC with IL-10 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected surface PD-L2 expression on tonsil-derived human follicular DCs (FDCs) (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: A representative lot competed against human PD-1 extracellular domain Ig fusion for the binding of exogenously expressed human PD-L2 on the surface of 300.19 murine pre-B lymphoma cells (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: DP-L2 blocking on the surface of PBMC-derived dendritic cells (DCs) by clone 24F.10C12 Fab fragment increased CD4+ T cell proliferation and cytokine production in allogenic cultures with immature DCs (iDC), mature DCs (mDC), and IL-10-treated mDCs. Dual blockage of both DP-L1 (by clone 29E.2A3 Fab fragment) and DP-L2 synergized the enhancing effect (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunohistsochemistry Analysis: A representative lot detected PD-L2 expression pattern in frozen human tonsil, placenta, fetal thymus and cardiac tissue sections (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunocytsochemistry Analysis: A representative lot detected an upregulated PD-L2 immunoreactivity in human CD14+ monocyte-derived macrophages (MDMs) following HIV-BaL infection, but not LPS stimulation by fluorescent immunocytochemistry using paraformaldehyde-fixed MDMs (Rodríguez-García, M., et al. (2011). J. Leukoc. Biol. 89(4) 507–515).
This Anti-PD-L2 Antibody, clone 24F.10C12 is validated for use in Western Blotting, Flow Cytometry, Neutralizing, Immunohistochemistry for the detection of PD-L2.
Research Category
Apoptosis & Cancer

Evaluated by Western Blotting in human thymus tissue lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected PD-L2 in 10 µg of human thymus tissue lysate.

Purified mouse monoclonal IgG2aκ antibody in buffer containing PBS without preservatives.
Format: Purified
Protein G Purified

Concentration: Please refer to lot specific datasheet.

100

mouse

purified immunoglobulin

primary antibodies

24F.10C12, monoclonal

human

flow cytometry: suitable
immunohistochemistry: suitable
neutralization: suitable
western blot: suitable

IgG2aκ

NP_079515.2

Q9BQ51

dry ice

~30 kDa observed. 28.85 kDa (isoform 1; PD-L2I), 18.76 kDa (isoform 2; PD-L2II), 18.64 kDa (isoform 3; PD-L2III) calculated.

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 2